🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans

Jeffrey Walch

Stock Analyst at Bernstein

(2.49)
# 3,053
Out of 5,162 analysts
41
Total ratings
80%
Success rate
4.1%
Average return

Stocks Rated by Jeffrey Walch

Summit Therapeutics
Nov 18, 2026
Downgraded: Sell
Price Target: $12 → $8.3
Current: $10.50
Upside: -20.95%
BioNTech SE
Nov 6, 2026
Reiterated: Hold
Price Target: $96
Current: $83.26
Upside: +15.30%
Revolution Medicines
Nov 4, 2026
Reiterated: Hold
Price Target: $179
Current: $159.82
Upside: +12.00%
Neurocrine Biosciences
Nov 3, 2026
Reiterated: Buy
Price Target: $218
Current: $162.86
Upside: +33.86%
Incyte
Nov 2, 2026
Reiterated: Hold
Price Target: $104 → $108
Current: $117.80
Upside: -8.32%
Regeneron Pharmaceuticals
Nov 2, 2026
Reiterated: Hold
Price Target: $812
Current: $945.53
Upside: -14.12%
Alnylam Pharmaceuticals
Oct 30, 2026
Downgraded: Hold
Price Target: $376 → $199
Current: $149.40
Upside: +33.20%
Biogen
Oct 19, 2026
Reiterated: Buy
Price Target: $236
Current: $251.41
Upside: -6.13%
Jazz Pharmaceuticals
Sep 25, 2026
Reiterated: Hold
Price Target: $229
Current: $247.77
Upside: -7.58%
Vertex Pharmaceuticals
Sep 25, 2026
Reiterated: Buy
Price Target: $608
Current: $536.45
Upside: +13.34%